- Report
- April 2023
- 119 Pages
Global
From €3500EUR$4,210USD£3,133GBP
- Report
- May 2023
- 113 Pages
Global
From €3500EUR$4,210USD£3,133GBP
- Newsletter
- August 2025
- 3 Pages
Global
From €117EUR$131USD£101GBP
- Newsletter
- August 2025
- 3 Pages
Europe
From €117EUR$131USD£101GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£732GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£732GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£732GBP
- Report
- January 2025
- 132 Pages
Global
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
United States
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
United Kingdom
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
South Korea
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
Japan
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
India
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
Germany
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
France
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
China
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
Brazil
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
Europe
From €846EUR$950USD£732GBP
- Report
- June 2024
- 70 Pages
Latin America
From €846EUR$950USD£732GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more